New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the Global ...

Cepheid is developing a rapid test, known as Xpert Carba-R, for detecting multidrug-resistant pathogens. The test has several advantages over existing diagnostic methods. The company successfully ...

Cepheid said Thursday it received de novo authorization for the only molecular test in the U.S. to detect hepatitis C virus RNA directly from fingerstick blood samples. The Food and Drug ...

Cepheid 's CPHD rapid influenza and RSV assay - the Xpert Flu+RSV Xpress test - recently won the U.S. FDA 510(k) marketing approval and the Clinical Laboratory Improvement Achievements (CLIA) waiver.

Researchers at the University of Washington have developed a rapid test that quickly detects hepatitis C, but insurance ...

SUNNYVALE, Calif., Dec. 8, 2022 /PRNewswire/ -- Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests. Two recently identified mutations in the matrix ...

Cepheid has supported TB testing worldwide for over 15 years. Xpert MTB/RIF, released in 2009 in collaboration with the Foundation for Innovative New Diagnostics (FIND), was a first-of-its-kind ...

SUNNYVALE, Calif., June 9, 2020 /PRNewswire/ -- Cepheid today announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the ...

Managing One of the Largest Enterovirus Testing Populations, Children's Medical Center Dallas Among Leading Institutions to Quickly Adopt Cepheid's SUNNYVALE, Calif ...

LONDON (Reuters) - The World Health Organization (WHO) gave its backing on Wednesday to a new molecular test for tuberculosis made by Cepheid which can rapidly diagnose TB, one of the world's biggest ...